(Q46576663)

23 December 2017

title

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone (English)

1 reference

23 December 2017

main subject

phase I clinical trial

0 references

author

Alexandre Harari

5

1 reference

23 December 2017

Jonathan L. Heeney

16

1 reference

23 December 2017

Wolfgang Stöhr

2

object named as

Wolfgang Stöhr

1 reference

23 December 2017

Giuseppe Pantaleo

20

object named as

Giuseppe Pantaleo

1 reference

23 December 2017

author name string

Sheena McCormack

1

1 reference

23 December 2017

Tristan Barber

3

1 reference

23 December 2017

Pierre-Alexandre Bart

4

1 reference

23 December 2017

Christiane Moog

6

1 reference

23 December 2017

Donatella Ciuffreda

7

1 reference

23 December 2017

Cristina Cellerai

8

1 reference

23 December 2017

Miranda Cowen

9

1 reference

23 December 2017

Romilda Gamboni

10

1 reference

23 December 2017

Séverine Burnet

11

1 reference

23 December 2017

Ken Legg

12

1 reference

23 December 2017

Elizabeth Brodnicki

13

1 reference

23 December 2017

Hans Wolf

14

1 reference

23 December 2017

Ralf Wagner

15

1 reference

23 December 2017

Marie-Joëlle Frachette

17

1 reference

23 December 2017

Jim Tartaglia

18

1 reference

23 December 2017

Abdel Babiker

19

1 reference

23 December 2017

Jonathan Weber

21

1 reference

23 December 2017

language of work or name

English

0 references

publication date

6 May 2008

1 reference

23 December 2017

published in

Vaccine

1 reference

23 December 2017

volume

26

1 reference

23 December 2017

issue

25

1 reference

23 December 2017

page(s)

3162-3174

1 reference

23 December 2017

Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

An HIV vaccine--evolving concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

Estimating the benefit of an HIV-1 vaccine that reduces viral load set point

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.072

10.1016/J.VACCINE.2008.02.072

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017